Atlas Trials

177Lu-TATE-RGD in Patients With SSTR2 and Integrin αVβ3 Positive Tumors

Clinical trial NCT06632873 · RECRUITING

Trial details

NCT number
NCT06632873
Sponsor
Peking Union Medical College Hospital
Status
RECRUITING
Phase
Early Phase 1
Study type
INTERVENTIONAL
SSTR2 and Integrin αVβ3 Positive Tumors
Start date
2024-09-01
Primary completion
2025-01-30
Enrollment
10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.